Company Overview

Viveve Medical, Inc. was a U.S.-based medical technology company focused on women’s health and non-invasive therapeutic treatments. The company developed and commercialized radiofrequency-based medical technologies intended to address women’s intimate health conditions, including vaginal laxity and aspects of sexual wellness. Viveve operated within the broader medical device and healthcare technology industries, with its business centered on proprietary energy-delivery systems and procedure-based physician services.

The company’s primary commercial product platform was the Viveve System, which used cryogen-cooled monopolar radiofrequency technology designed for use in women’s health procedures. Revenue was historically derived from system sales, disposable treatment tips, and related service activities to healthcare providers and clinics. Viveve positioned itself as a differentiated participant in the women’s health device market by focusing on minimally invasive treatments and physician-administered procedures. Public filings indicate the company evolved from an early-stage medical device developer into a commercialization-stage enterprise, though its operating scale and financial position remained limited relative to larger medical technology peers. Data regarding the company’s current operating status is inconclusive based on available public sources.

Business Operations

Viveve Medical’s operations were primarily organized around its women’s health technology platform and commercialization activities for the Viveve System. The company generated revenue through the sale or placement of capital equipment, recurring consumable treatment components, and support services provided to medical practices. Its customer base included gynecologists, cosmetic surgeons, wellness clinics, and other healthcare providers offering elective women’s health procedures.

The company maintained operations in the United States while also pursuing international commercialization opportunities through distributors and regional partners in selected overseas markets. Viveve controlled intellectual property associated with its radiofrequency and cooling technologies and relied on regulatory clearances in various jurisdictions to support commercialization. Public disclosures referenced relationships with distributors and clinical collaborators, though information regarding large-scale joint ventures or strategic manufacturing partnerships remains limited in publicly available materials.

Strategic Position & Investments

Viveve Medical’s strategic direction focused on expanding the clinical adoption of energy-based women’s health therapies and generating additional clinical evidence to support physician use and regulatory positioning. The company invested in clinical studies and regulatory initiatives tied to women’s sexual health and pelvic wellness indications. Its strategy emphasized physician education, market awareness, and recurring procedure utilization associated with consumable treatment products.

Historically, Viveve pursued growth through technology development, international market expansion, and capital raises intended to fund commercialization activities. Public filings and investor communications referenced efforts to broaden the clinical applications of its radiofrequency platform and strengthen intellectual property protections. However, available public information indicates the company faced operational and financial challenges common among smaller medical device firms, including commercialization scale constraints and capital requirements. Information regarding significant acquisitions or large portfolio holdings is inconclusive based on available public sources.

Geographic Footprint

Viveve Medical was headquartered in the United States, with principal corporate operations historically located in California. The company marketed its technology domestically and pursued international distribution arrangements in parts of Asia-Pacific, Europe, and Latin America through third-party commercial relationships and regional healthcare distributors.

The company’s international presence was more limited than multinational medical device competitors, but public disclosures indicated efforts to expand physician adoption outside the U.S. through regulatory approvals and localized distribution strategies. Its operational influence was concentrated primarily in developed healthcare markets where elective medical procedures and women’s wellness services had established private-pay demand characteristics.

Leadership & Governance

Viveve Medical’s leadership historically included executives with backgrounds in medical devices, commercialization, healthcare operations, and public company management. The company’s governance structure followed a standard publicly traded corporate framework with executive management oversight and a board of directors responsible for strategic direction, financing decisions, and regulatory governance.

Key executives identified in public filings and company disclosures included:

• Scott Durbin – Chief Executive Officer
• Patricia Scheller – Chief Financial Officer
• John A. McCurdy – Chairman of the Board

Leadership communications emphasized advancing women’s health innovation, expanding clinical validation for the company’s technology platform, and increasing physician adoption in both domestic and international markets. Information regarding more recent executive changes or the company’s present governance structure is inconclusive based on available public sources.